D
Enzo Biochem, Inc.
ENZ
$1.00
-$0.04-3.85%
D
Sell
12/18/2023Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D from D+ on 12/18/2023 due to a large decline in the growth index, total return index and efficiency index. EBIT declined 164.29% from $8.52M to -$5.48M, net income declined 111.52% from $57.43M to -$6.62M, and earnings per share declined from $1.1707 to -$0.1318.
Enzo Biochem, Inc. (ENZ) was downgraded to D from D+ on 12/18/2023 due to a large decline in the growth index, total return index and efficiency index. EBIT declined 164.29% from $8.52M to -$5.48M, net income declined 111.52% from $57.43M to -$6.62M, and earnings per share declined from $1.1707 to -$0.1318.
D
Sell
11/9/2023Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to D+ from E+ on 11/9/2023 due to a significant increase in the valuation index, efficiency index and growth index. Earnings per share increased from -$0.3075 to $1.1706, net income increased 478.15% from -$15.19M to $57.43M, and EBIT increased 169.04% from -$15.65M to $10.8M.
Enzo Biochem, Inc. (ENZ) was upgraded to D+ from E+ on 11/9/2023 due to a significant increase in the valuation index, efficiency index and growth index. Earnings per share increased from -$0.3075 to $1.1706, net income increased 478.15% from -$15.19M to $57.43M, and EBIT increased 169.04% from -$15.65M to $10.8M.
E
Sell
7/17/2023Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to E+ from D- on 7/17/2023 due to a decline in the volatility index and total return index.
Enzo Biochem, Inc. (ENZ) was downgraded to E+ from D- on 7/17/2023 due to a decline in the volatility index and total return index.
D
Sell
6/20/2023Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D- from D on 6/20/2023 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 0.23 to 0.59, the quick ratio declined from 0.49 to 0.29, and net income declined 34.16% from -$11.32M to -$15.19M.
Enzo Biochem, Inc. (ENZ) was downgraded to D- from D on 6/20/2023 due to a decline in the solvency index, valuation index and efficiency index. Debt to equity increased from 0.23 to 0.59, the quick ratio declined from 0.49 to 0.29, and net income declined 34.16% from -$11.32M to -$15.19M.
D
Sell
5/1/2023Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to D from D- on 5/1/2023 due to a noticeable increase in the volatility index and total return index.
Enzo Biochem, Inc. (ENZ) was upgraded to D from D- on 5/1/2023 due to a noticeable increase in the volatility index and total return index.
D
Sell
12/14/2022Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D- from D on 12/14/2022 due to a decline in the efficiency index, total return index and solvency index. The quick ratio declined from 1.35 to 0.98, net income declined 26.11% from -$8.43M to -$10.64M, and debt to equity increased from 0.14 to 0.17.
Enzo Biochem, Inc. (ENZ) was downgraded to D- from D on 12/14/2022 due to a decline in the efficiency index, total return index and solvency index. The quick ratio declined from 1.35 to 0.98, net income declined 26.11% from -$8.43M to -$10.64M, and debt to equity increased from 0.14 to 0.17.
D
Sell
6/10/2022Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D from D+ on 6/10/2022 due to a significant decline in the growth index, efficiency index and total return index. EBIT declined 1,306.28% from -$223 to -$3.14M, net income declined 82.82% from -$2.66M to -$4.85M, and earnings per share declined from -$0.0548 to -$0.1.
Enzo Biochem, Inc. (ENZ) was downgraded to D from D+ on 6/10/2022 due to a significant decline in the growth index, efficiency index and total return index. EBIT declined 1,306.28% from -$223 to -$3.14M, net income declined 82.82% from -$2.66M to -$4.85M, and earnings per share declined from -$0.0548 to -$0.1.
D
Sell
4/20/2022Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D+ from C- on 4/20/2022 due to a major decline in the valuation index, total return index and efficiency index. Net income declined 14.49% from -$2.32M to -$2.66M, and total capital declined 2.86% from $88.63M to $86.1M.
Enzo Biochem, Inc. (ENZ) was downgraded to D+ from C- on 4/20/2022 due to a major decline in the valuation index, total return index and efficiency index. Net income declined 14.49% from -$2.32M to -$2.66M, and total capital declined 2.86% from $88.63M to $86.1M.
C
Hold
2/11/2022Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to C- from D+ on 2/11/2022 due to an increase in the volatility index and total return index.
Enzo Biochem, Inc. (ENZ) was upgraded to C- from D+ on 2/11/2022 due to an increase in the volatility index and total return index.
D
Sell
1/27/2022Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D+ from C- on 1/27/2022 due to a decline in the valuation index and volatility index.
Enzo Biochem, Inc. (ENZ) was downgraded to D+ from C- on 1/27/2022 due to a decline in the valuation index and volatility index.
C
Hold
1/11/2022Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to C- from D+ on 1/11/2022 due to an increase in the valuation index and volatility index.
Enzo Biochem, Inc. (ENZ) was upgraded to C- from D+ on 1/11/2022 due to an increase in the valuation index and volatility index.
D
Sell
12/22/2021Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D+ from C- on 12/22/2021 due to a decline in the total return index and volatility index.
Enzo Biochem, Inc. (ENZ) was downgraded to D+ from C- on 12/22/2021 due to a decline in the total return index and volatility index.
C
Hold
12/16/2021Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to C- from C on 12/16/2021 due to a large decline in the valuation index, growth index and volatility index. Operating cash flow declined 5,695.37% from $108 to -$6.04M, and earnings per share declined from $0.0596 to -$0.05.
Enzo Biochem, Inc. (ENZ) was downgraded to C- from C on 12/16/2021 due to a large decline in the valuation index, growth index and volatility index. Operating cash flow declined 5,695.37% from $108 to -$6.04M, and earnings per share declined from $0.0596 to -$0.05.
C
Hold
12/9/2021Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to C from C- on 12/9/2021 due to an increase in the total return index and volatility index.
Enzo Biochem, Inc. (ENZ) was upgraded to C from C- on 12/9/2021 due to an increase in the total return index and volatility index.
C
Hold
11/18/2021Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to C- from C on 11/18/2021 due to a decline in the total return index and valuation index.
Enzo Biochem, Inc. (ENZ) was downgraded to C- from C on 11/18/2021 due to a decline in the total return index and valuation index.
C
Hold
11/3/2021Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to C from C- on 11/3/2021 due to a significant increase in the valuation index, total return index and efficiency index. Net income increased 62.91% from $2.01M to $3.27M.
Enzo Biochem, Inc. (ENZ) was upgraded to C from C- on 11/3/2021 due to a significant increase in the valuation index, total return index and efficiency index. Net income increased 62.91% from $2.01M to $3.27M.
C
Hold
8/27/2021Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to C- from D+ on 8/27/2021 due to an increase in the total return index and volatility index.
Enzo Biochem, Inc. (ENZ) was upgraded to C- from D+ on 8/27/2021 due to an increase in the total return index and volatility index.
D
Sell
6/11/2021Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to D+ from D on 6/11/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 381.34% from -$820 to $2.31M, EBIT increased 20.88% from $1.71M to $2.07M, and total revenue increased 4.23% from $31.47M to $32.8M.
Enzo Biochem, Inc. (ENZ) was upgraded to D+ from D on 6/11/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 381.34% from -$820 to $2.31M, EBIT increased 20.88% from $1.71M to $2.07M, and total revenue increased 4.23% from $31.47M to $32.8M.
D
Sell
12/1/2020Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to D from D- on 12/1/2020 due to an increase in the volatility index.
Enzo Biochem, Inc. (ENZ) was upgraded to D from D- on 12/1/2020 due to an increase in the volatility index.
D
Sell
11/10/2020Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D- from D on 11/10/2020 due to a decline in the volatility index and total return index.
Enzo Biochem, Inc. (ENZ) was downgraded to D- from D on 11/10/2020 due to a decline in the volatility index and total return index.
D
Sell
10/26/2020Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to D from D- on 10/26/2020 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.21 to -$0.07, EBIT increased 54.43% from -$9.72M to -$4.43M, and total revenue increased 15.52% from $16.9M to $19.53M.
Enzo Biochem, Inc. (ENZ) was upgraded to D from D- on 10/26/2020 due to an increase in the growth index, volatility index and valuation index. Earnings per share increased from -$0.21 to -$0.07, EBIT increased 54.43% from -$9.72M to -$4.43M, and total revenue increased 15.52% from $16.9M to $19.53M.
D
Sell
6/11/2020Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D- from D on 6/11/2020 due to a large decline in the efficiency index, growth index and solvency index. Debt to equity increased from 0.13 to 0.26, earnings per share declined from -$0.1616 to -$0.21, and net income declined 28.27% from -$7.69M to -$9.86M.
Enzo Biochem, Inc. (ENZ) was downgraded to D- from D on 6/11/2020 due to a large decline in the efficiency index, growth index and solvency index. Debt to equity increased from 0.13 to 0.26, earnings per share declined from -$0.1616 to -$0.21, and net income declined 28.27% from -$7.69M to -$9.86M.
D
Sell
10/16/2019Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D from D+ on 10/16/2019 due to a noticeable decline in the growth index and efficiency index. Earnings per share declined from $0.4692 to -$0.1188, net income declined 124.19% from $22.27M to -$5.39M, and operating cash flow declined 113.91% from $22.83M to -$3.18M.
Enzo Biochem, Inc. (ENZ) was downgraded to D from D+ on 10/16/2019 due to a noticeable decline in the growth index and efficiency index. Earnings per share declined from $0.4692 to -$0.1188, net income declined 124.19% from $22.27M to -$5.39M, and operating cash flow declined 113.91% from $22.83M to -$3.18M.
D
Sell
6/12/2019Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to D+ from D on 6/12/2019 due to a noticeable increase in the growth index, valuation index and efficiency index. Net income increased 364.81% from -$8.41M to $22.27M, operating cash flow increased 364.16% from -$8.64M to $22.83M, and earnings per share increased from -$0.1781 to $0.4692.
Enzo Biochem, Inc. (ENZ) was upgraded to D+ from D on 6/12/2019 due to a noticeable increase in the growth index, valuation index and efficiency index. Net income increased 364.81% from -$8.41M to $22.27M, operating cash flow increased 364.16% from -$8.64M to $22.83M, and earnings per share increased from -$0.1781 to $0.4692.
D
Sell
9/20/2018Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D from D+ on 9/20/2018 due to a substantial decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.0192 to -$0.0641, and total revenue declined 4.91% from $26.95M to $25.63M.
Enzo Biochem, Inc. (ENZ) was downgraded to D from D+ on 9/20/2018 due to a substantial decline in the total return index, growth index and volatility index. Earnings per share declined from -$0.0192 to -$0.0641, and total revenue declined 4.91% from $26.95M to $25.63M.
D
Sell
11/1/2017Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to D+ from C- on 11/1/2017 due to a major decline in the total return index and volatility index.
Enzo Biochem, Inc. (ENZ) was downgraded to D+ from C- on 11/1/2017 due to a major decline in the total return index and volatility index.
C
Hold
9/29/2017Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to C- from B- on 9/29/2017 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 151.98% from -$227 to -$572.
Enzo Biochem, Inc. (ENZ) was downgraded to C- from B- on 9/29/2017 due to a significant decline in the valuation index, growth index and efficiency index. EBIT declined 151.98% from -$227 to -$572.
B
Buy
5/16/2017Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to B- from C+ on 5/16/2017 due to an increase in the total return index and volatility index.
Enzo Biochem, Inc. (ENZ) was upgraded to B- from C+ on 5/16/2017 due to an increase in the total return index and volatility index.
C
Hold
5/1/2017Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to C+ from B- on 5/1/2017 due to a noticeable decline in the total return index, valuation index and efficiency index.
Enzo Biochem, Inc. (ENZ) was downgraded to C+ from B- on 5/1/2017 due to a noticeable decline in the total return index, valuation index and efficiency index.
B
Buy
3/14/2017Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to B- from C+ on 3/14/2017 due to a large increase in the total return index, growth index and efficiency index. Earnings per share increased from -$0.0319 to -$0.0227, net income increased 28.56% from -$1.47M to -$1.05M, and EBIT increased 19.79% from -$1.26M to -$1.01M.
Enzo Biochem, Inc. (ENZ) was upgraded to B- from C+ on 3/14/2017 due to a large increase in the total return index, growth index and efficiency index. Earnings per share increased from -$0.0319 to -$0.0227, net income increased 28.56% from -$1.47M to -$1.05M, and EBIT increased 19.79% from -$1.26M to -$1.01M.
C
Hold
2/28/2017Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to C+ from B- on 2/28/2017 due to a major decline in the total return index.
Enzo Biochem, Inc. (ENZ) was downgraded to C+ from B- on 2/28/2017 due to a major decline in the total return index.
B
Buy
2/13/2017Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to B- from C+ on 2/13/2017 due to a large increase in the total return index, valuation index and volatility index.
Enzo Biochem, Inc. (ENZ) was upgraded to B- from C+ on 2/13/2017 due to a large increase in the total return index, valuation index and volatility index.
C
Hold
1/19/2017Downgrade
Enzo Biochem, Inc. (ENZ) was downgraded to C+ from B- on 1/19/2017 due to a noticeable decline in the total return index and valuation index.
Enzo Biochem, Inc. (ENZ) was downgraded to C+ from B- on 1/19/2017 due to a noticeable decline in the total return index and valuation index.
B
Buy
1/4/2017Upgraded
Enzo Biochem, Inc. (ENZ) was upgraded to B- from C+ on 1/4/2017 due to a significant increase in the total return index, solvency index and efficiency index.
Enzo Biochem, Inc. (ENZ) was upgraded to B- from C+ on 1/4/2017 due to a significant increase in the total return index, solvency index and efficiency index.
C
Hold
10/14/2016Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 10/14/2016 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 1,808.51% from -$2.12M to $36.14M, earnings per share increased from -$0.05 to $0.7688, and operating cash flow increased 1,280.46% from -$3.06M to $36.12M.
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 10/14/2016 due to a significant increase in the valuation index, growth index and efficiency index. Net income increased 1,808.51% from -$2.12M to $36.14M, earnings per share increased from -$0.05 to $0.7688, and operating cash flow increased 1,280.46% from -$3.06M to $36.12M.
C
Hold
8/18/2016Downgrade
Enzo Biochem Inc. (ENZ) was downgraded to C from C+ on 8/18/2016 due to a decline in the total return index, valuation index and growth index. Operating cash flow declined 144.28% from $6.91M to -$3.06M, and earnings per share declined from $0.1483 to -$0.05.
Enzo Biochem Inc. (ENZ) was downgraded to C from C+ on 8/18/2016 due to a decline in the total return index, valuation index and growth index. Operating cash flow declined 144.28% from $6.91M to -$3.06M, and earnings per share declined from $0.1483 to -$0.05.
C
Hold
5/16/2016Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 5/16/2016 due to an increase in the total return index and volatility index.
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 5/16/2016 due to an increase in the total return index and volatility index.
C
Hold
4/29/2016Downgrade
Enzo Biochem Inc. (ENZ) was downgraded to C from C+ on 4/29/2016 due to a decline in the total return index and valuation index.
Enzo Biochem Inc. (ENZ) was downgraded to C from C+ on 4/29/2016 due to a decline in the total return index and valuation index.
C
Hold
4/7/2016Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 4/7/2016 due to a significant increase in the total return index and volatility index.
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 4/7/2016 due to a significant increase in the total return index and volatility index.
C
Hold
3/11/2016Downgrade
Enzo Biochem Inc. (ENZ) was downgraded to C from B on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
Enzo Biochem Inc. (ENZ) was downgraded to C from B on 3/11/2016 due to a significant decline in the volatility index, total return index and valuation index.
B
Buy
3/9/2016Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to B from B- on 3/9/2016 due to a significant increase in the valuation index, growth index and solvency index. EBIT increased 93.8% from -$2.16M to -$4.19M, earnings per share increased from $0.0962 to $0.1483, and debt to equity declined from 0.08 to 0.06.
Enzo Biochem Inc. (ENZ) was upgraded to B from B- on 3/9/2016 due to a significant increase in the valuation index, growth index and solvency index. EBIT increased 93.8% from -$2.16M to -$4.19M, earnings per share increased from $0.0962 to $0.1483, and debt to equity declined from 0.08 to 0.06.
B
Buy
2/8/2016Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to B- from C+ on 2/8/2016 due to a substantial increase in the total return index and valuation index.
Enzo Biochem Inc. (ENZ) was upgraded to B- from C+ on 2/8/2016 due to a substantial increase in the total return index and valuation index.
C
Hold
1/29/2016Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 1/29/2016 due to an increase in the total return index and volatility index.
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 1/29/2016 due to an increase in the total return index and volatility index.
C
Hold
1/12/2016Downgrade
Enzo Biochem Inc. (ENZ) was downgraded to C from C+ on 1/12/2016 due to a decline in the total return index.
Enzo Biochem Inc. (ENZ) was downgraded to C from C+ on 1/12/2016 due to a decline in the total return index.
C
Hold
12/28/2015Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 12/28/2015 due to an increase in the total return index.
Enzo Biochem Inc. (ENZ) was upgraded to C+ from C on 12/28/2015 due to an increase in the total return index.
C
Hold
12/10/2015Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to C from D+ on 12/10/2015 due to a major increase in the valuation index, efficiency index and growth index. Operating cash flow increased 194.25% from $4.47M to $13.15M, and total capital increased 10% from $46.67M to $51.34M.
Enzo Biochem Inc. (ENZ) was upgraded to C from D+ on 12/10/2015 due to a major increase in the valuation index, efficiency index and growth index. Operating cash flow increased 194.25% from $4.47M to $13.15M, and total capital increased 10% from $46.67M to $51.34M.
D
Sell
11/23/2015Downgrade
Enzo Biochem Inc. (ENZ) was downgraded to D+ from C- on 11/23/2015 due to a decline in the valuation index.
Enzo Biochem Inc. (ENZ) was downgraded to D+ from C- on 11/23/2015 due to a decline in the valuation index.
C
Hold
10/29/2015Downgrade
Enzo Biochem Inc. (ENZ) was downgraded to C- from C on 10/29/2015 due to a significant decline in the efficiency index, valuation index and solvency index.
Enzo Biochem Inc. (ENZ) was downgraded to C- from C on 10/29/2015 due to a significant decline in the efficiency index, valuation index and solvency index.
C
Hold
10/14/2015Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to C from D on 10/14/2015 due to a significant increase in the efficiency index, volatility index and growth index. Total revenue increased 414.03% from $23.99M to $123.3M, and total capital increased 19.58% from $38.15M to $45.62M.
Enzo Biochem Inc. (ENZ) was upgraded to C from D on 10/14/2015 due to a significant increase in the efficiency index, volatility index and growth index. Total revenue increased 414.03% from $23.99M to $123.3M, and total capital increased 19.58% from $38.15M to $45.62M.
D
Sell
3/13/2015Downgrade
Enzo Biochem Inc. (ENZ) was downgraded to D from D+ on 3/13/2015 due to a decline in the volatility index, efficiency index and valuation index. Total capital declined 2.92% from $40.15M to $38.98M.
Enzo Biochem Inc. (ENZ) was downgraded to D from D+ on 3/13/2015 due to a decline in the volatility index, efficiency index and valuation index. Total capital declined 2.92% from $40.15M to $38.98M.
D
Sell
2/24/2015Upgraded
Enzo Biochem Inc. (ENZ) was upgraded to D+ from D on 2/24/2015 due to a major increase in the total return index, volatility index and growth index. Earnings per share increased from -$0.072 to -$0.0837.
Enzo Biochem Inc. (ENZ) was upgraded to D+ from D on 2/24/2015 due to a major increase in the total return index, volatility index and growth index. Earnings per share increased from -$0.072 to -$0.0837.
NYSE
05/06/2024 9:49AM Eastern
Quotes delayed
